Baseline characteristics of patients according to the absolute lymphocyte count at day 15 (ALC-15) after ASCT
| Characteristics . | ALC-15 < 500 cells/μL (n = 86) . | ALC-15 ≥ 500 cells/μL (n = 59) . | P . | |||
|---|---|---|---|---|---|---|
| Age (y) | ||||||
| Median (range) | 55 (35-69) | 55 (31-71) | 0.88 | |||
| Sex | ||||||
| Females | 32 | 27 | 0.50 | |||
| Males | 52 | 32 | ||||
| Prognostic factors for amyloidosis | ||||||
| Age (y) | ||||||
| ≥50 | 63 | 40 | 0.58 | |||
| <50 | 23 | 19 | ||||
| Albumin (g/dl) | ||||||
| ≥3.5 | 20 | 10 | 0.41 | |||
| <3.5 | 66 | 49 | ||||
| Alkaline (units/L) phosphatase | ||||||
| >375 | 17 | 7 | 0.26 | |||
| ≤375 | 69 | 52 | ||||
| β-2 microglobulin (mg/L) | ||||||
| ≥2.7 | 29 | 15 | 0.36 | |||
| <2.7 | 57 | 44 | ||||
| Bone marrow plasma cells (%) | ||||||
| >20 | 15 | 5 | 0.15 | |||
| ≤20 | 71 | 54 | ||||
| Circulating plasma cells (%) | ||||||
| >1 | 3 | 2 | 0.97 | |||
| ≤1 | 83 | 57 | ||||
| C-reactive protein (mg/L) | ||||||
| >0.8 | 12 | 8 | 0.95 | |||
| ≤0.8 | 74 | 51 | ||||
| Creatinine (mg/L) | ||||||
| >2.0 | 9 | 1 | 0.05 | |||
| ≤2.0 | 77 | 58 | ||||
| Ejection fraction (%) | ||||||
| ≥60 | 66 | 48 | 0.54 | |||
| <60 | 26 | 11 | ||||
| Interventricular septal thickness (mm) | ||||||
| ≥15 | 26 | 14 | 0.45 | |||
| <15 | 60 | 45 | ||||
| LDH | ||||||
| Elevated | 23 | 6 | 0.02 | |||
| Normal for age/sex | 63 | 53 | ||||
| No. organs involved | ||||||
| >2 | 15 | 11 | 0.85 | |||
| ≤2 | 71 | 48 | ||||
| Plasma cell labeling index (%) | ||||||
| ≥1 | 5 | 2 | 0.70 | |||
| <1 | 81 | 57 | ||||
| Serum light chain by immunofixation | ||||||
| λ | 46 | 31 | 0.79 | |||
| κ | 13 | 11 | ||||
| None | 27 | 16 | ||||
| Serum M spike (g/dl) | ||||||
| >1.0 | 18 | 6 | 0.11 | |||
| ≤1.0 | 68 | 53 | ||||
| 24 h urine protein (g) | ||||||
| >3.0 | 48 | 34 | 0.87 | |||
| ≤3.0 | 38 | 25 | ||||
| Troponin T* (μg/L) | ||||||
| ≥0.035 | 12 | 4 | 0.20 | |||
| <0.035 | 50 | 36 | ||||
| Urine light chain by immunofixation | ||||||
| λ | 57 | 41 | 0.79 | |||
| κ | 20 | 11 | ||||
| None | 9 | 7 | ||||
| Urine M protein (g/d) | ||||||
| >0.25 | 31 | 23 | 0.73 | |||
| ≤0.25 | 55 | 36 | ||||
| Free κ light chain before ASCT† (g/L) | ||||||
| >0.026 | 24 | 18 | 0.80 | |||
| ≤0.026 | 15 | 9 | ||||
| >0.019 | 14 | 7 | 0.43 | |||
| ≤0.019 | 25 | 20 | ||||
| No. prior therapies | ||||||
| 0 | 58 | 38 | 0.59 | |||
| 1 | 23 | 16 | ||||
| 2 | 5 | 4 | ||||
| 3 | 0 | 1 | ||||
| Stem cell mobilization regimens | ||||||
| Cytoxan/GM-CSF | 16 | 14 | 0.46 | |||
| G-CSF | 70 | 45 | ||||
| Conditioning regimens | ||||||
| Melphalan/TBI | 6 | 9 | 0.05 | |||
| Melphalan 200 | 46 | 38 | ||||
| Melphalan 160 | 0 | 1 | ||||
| Melphalan 140 | 28 | 9 | ||||
| Melphalan 100 | 6 | 2 | ||||
| Characteristics . | ALC-15 < 500 cells/μL (n = 86) . | ALC-15 ≥ 500 cells/μL (n = 59) . | P . | |||
|---|---|---|---|---|---|---|
| Age (y) | ||||||
| Median (range) | 55 (35-69) | 55 (31-71) | 0.88 | |||
| Sex | ||||||
| Females | 32 | 27 | 0.50 | |||
| Males | 52 | 32 | ||||
| Prognostic factors for amyloidosis | ||||||
| Age (y) | ||||||
| ≥50 | 63 | 40 | 0.58 | |||
| <50 | 23 | 19 | ||||
| Albumin (g/dl) | ||||||
| ≥3.5 | 20 | 10 | 0.41 | |||
| <3.5 | 66 | 49 | ||||
| Alkaline (units/L) phosphatase | ||||||
| >375 | 17 | 7 | 0.26 | |||
| ≤375 | 69 | 52 | ||||
| β-2 microglobulin (mg/L) | ||||||
| ≥2.7 | 29 | 15 | 0.36 | |||
| <2.7 | 57 | 44 | ||||
| Bone marrow plasma cells (%) | ||||||
| >20 | 15 | 5 | 0.15 | |||
| ≤20 | 71 | 54 | ||||
| Circulating plasma cells (%) | ||||||
| >1 | 3 | 2 | 0.97 | |||
| ≤1 | 83 | 57 | ||||
| C-reactive protein (mg/L) | ||||||
| >0.8 | 12 | 8 | 0.95 | |||
| ≤0.8 | 74 | 51 | ||||
| Creatinine (mg/L) | ||||||
| >2.0 | 9 | 1 | 0.05 | |||
| ≤2.0 | 77 | 58 | ||||
| Ejection fraction (%) | ||||||
| ≥60 | 66 | 48 | 0.54 | |||
| <60 | 26 | 11 | ||||
| Interventricular septal thickness (mm) | ||||||
| ≥15 | 26 | 14 | 0.45 | |||
| <15 | 60 | 45 | ||||
| LDH | ||||||
| Elevated | 23 | 6 | 0.02 | |||
| Normal for age/sex | 63 | 53 | ||||
| No. organs involved | ||||||
| >2 | 15 | 11 | 0.85 | |||
| ≤2 | 71 | 48 | ||||
| Plasma cell labeling index (%) | ||||||
| ≥1 | 5 | 2 | 0.70 | |||
| <1 | 81 | 57 | ||||
| Serum light chain by immunofixation | ||||||
| λ | 46 | 31 | 0.79 | |||
| κ | 13 | 11 | ||||
| None | 27 | 16 | ||||
| Serum M spike (g/dl) | ||||||
| >1.0 | 18 | 6 | 0.11 | |||
| ≤1.0 | 68 | 53 | ||||
| 24 h urine protein (g) | ||||||
| >3.0 | 48 | 34 | 0.87 | |||
| ≤3.0 | 38 | 25 | ||||
| Troponin T* (μg/L) | ||||||
| ≥0.035 | 12 | 4 | 0.20 | |||
| <0.035 | 50 | 36 | ||||
| Urine light chain by immunofixation | ||||||
| λ | 57 | 41 | 0.79 | |||
| κ | 20 | 11 | ||||
| None | 9 | 7 | ||||
| Urine M protein (g/d) | ||||||
| >0.25 | 31 | 23 | 0.73 | |||
| ≤0.25 | 55 | 36 | ||||
| Free κ light chain before ASCT† (g/L) | ||||||
| >0.026 | 24 | 18 | 0.80 | |||
| ≤0.026 | 15 | 9 | ||||
| >0.019 | 14 | 7 | 0.43 | |||
| ≤0.019 | 25 | 20 | ||||
| No. prior therapies | ||||||
| 0 | 58 | 38 | 0.59 | |||
| 1 | 23 | 16 | ||||
| 2 | 5 | 4 | ||||
| 3 | 0 | 1 | ||||
| Stem cell mobilization regimens | ||||||
| Cytoxan/GM-CSF | 16 | 14 | 0.46 | |||
| G-CSF | 70 | 45 | ||||
| Conditioning regimens | ||||||
| Melphalan/TBI | 6 | 9 | 0.05 | |||
| Melphalan 200 | 46 | 38 | ||||
| Melphalan 160 | 0 | 1 | ||||
| Melphalan 140 | 28 | 9 | ||||
| Melphalan 100 | 6 | 2 | ||||